We're proud to partner with the ALS Network and their President & CEO, Sheri Strahl, as they invest in #ALSResearch and put people living with ALS and caregivers first. Read Sheri's story and see how our partnership is accelerating research and impact:

The work Dr. Javier Oroz and his team are doing to detect toxic, misfolded TDP-43, a protein involved in most ALS cases, is powered by cerebrospinal fluid (#CSF) provided by participants in our ALS Global Research Initiative (#AGRI). Learn more:

Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.

Every breakthrough in #ALSResearch starts with participation. By joining the ALS Global Research Initiative, the largest global ALS study, your samples are put to work immediately—fueling discoveries that can’t afford to wait. 🔗 Learn more & join today:

For Frances Aponte, epidemiologist and lead site coordinator for the Target ALS Global Natural History Study in Puerto Rico, every conversation is an opportunity to build trust, answer questions, and show why participation matters. Join today:

When you join the ALS Global Research Initiative (#AGRI), your participation fuels real progress. Unlike other studies where samples can sit unused for years, the information you provide is made available to scientists worldwide right away. Learn more:

The Target ALS Data Engine is a powerful tool for #ALSResearch, but it wouldn’t exist without the people, like Cooper Penner, who participate in our ALS Global Research Initiative (#AGRI). Learn more about AGRI and how to participate:

Scientist and mom Maria Bloom, joined the Target ALS Global Natural History Study (#GNHS) as a healthy control to be a part of something bigger. Join her as we build the ALS Global Research Initiative (#AGRI), the largest, most inclusive ALS study ever:

At Target ALS, we believe that research is the highest form of care. Why? Because every breakthrough and every improvement in quality of life for people with #ALS begins with research. See the impact of our ALS Global Research Initiative (#AGRI):

The Target ALS Global Natural History Study, part of our ALS Global Research Initiative (#AGRI), is the largest, most inclusive #ALS study in the world, spanning 14 sites across continents and representing diverse populations often left out of research.

For participants in the Global Natural History Study (#GNHS), part of our ALS Global Research Initiative (AGRI), every visit is a step toward answers, treatments, and hope for people living with #ALS worldwide. Learn about how you can participate today:

Every discovery in #ALSResearch starts with you. Through the ALS Global Research Initiative (#AGRI), participants—people living with #ALS and healthy volunteers—are creating one of the most powerful resources in ALS research. Learn about AGRI today:

Dr. Marc Gotkine is a principal investigator in our Global Natural History Study, a cornerstone of our ALS Global Research Initiative (#AGRI)—the largest global #ALSResearch study. See how this collaborative effort is unlocking information and treatments:.

In #ALSResearch, time matters. In other studies, samples can sit for years. Through #AGRI, participant samples are ready to go directly from the clinic into the hands of researchers —fueling discoveries now. Learn more: . #EveryoneLives

The largest, most inclusive #ALSResearch study yet: our #GlobalNaturalHistoryStudy. With 14+ global sites and 30% non-Caucasian participants, we’re united under one mission—#EveryoneLives. Together, we’re changing the future of #ALS. Learn more: #AGRI

An international team of scientists led is working to uncover the earliest biological clues of #ALS and #FTD. Learn how this global partnership could revolutionize diagnosis and treatment monitoring for ALS and FTD by making invisible pathology measurable:

A global team of researchers is using AI, advanced imaging, and genetic screening to understand what causes ALS and how to stop it. Read about how they're turning deep cell biology into real-world solutions:

At our 2025 Annual Meeting, Denali Therapeutics shared results from their DNL343 clinical trial. While the therapy, designed to target the integrated stress response, did not meet its endpoints, the study still provides critical insights for #ALSResearch:

A groundbreaking study—by scientists powered by Target ALS—is shifting how we view inflammation in ALS as something neurons may cause through their own immune responses. Learn how research findings in the study can reshape the future of #ALS treatment:

Dr. Frank Walsh, a pioneering force in neuroscience, pharma, and biotech, has spent his career pushing boundaries. See how Frank is now using his experience and passion to accelerate progress for #ALSResearch as a member of our Target ALS team.

We're proud to partner with @End_The_Legacy, a patient-led organization founded by individuals with deeply personal ties to familial ALS and FTD. Learn how we're closing gaps in inherited ALS research and lifting up patient voices: